![Laurent Lavigne du Cadet](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Laurent Lavigne du Cadet
Financieel Directeur/CFO bij NeuroCytonix, Inc.
Actieve functies van Laurent Lavigne du Cadet
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
NeuroCytonix, Inc.
![]() NeuroCytonix, Inc. BiotechnologyHealth Technology NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO. | Operationeel Directeur | - | - |
Financieel Directeur/CFO | - | - |
Loopbaan van Laurent Lavigne du Cadet
Statistieken
Internationaal
Verenigde Staten | 2 |
Operationeel
Chief Operating Officer | 1 |
Director of Finance/CFO | 1 |
Sectoraal
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
NeuroCytonix, Inc.
![]() NeuroCytonix, Inc. BiotechnologyHealth Technology NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO. | Health Technology |